|
1
|
Tarkkanen M, Karhu R, Kallioniemi A,
Elomaa I, Kivioja AH, Nevalainen J, Böhling T, Karaharju E,
Hyytinen E, Knuutila S, et al: Gains and losses of DNA sequences in
osteosarcomas by comparative genomic hybridization. Cancer Res.
55:1334–1338. 1995.PubMed/NCBI
|
|
2
|
Al-Romaih K, Bayani J, Vorobyova J,
Karaskova J, Park PC, Zielenska M and Squire JA: Chromosomal
instability in osteosarcoma and its association with centrosome
abnormalities. Cancer Genet Cytogenet. 144:91–99. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ragland BD, Bell WC, Lopez RR and Siegal
GP: Cytogenetics and molecular biology of osteosarcoma. Lab Invest.
82:365–373. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He JP, Hao Y, Wang XL, Yang XJ, Shao JF,
Guo FJ and Feng JX: Review of the molecular pathogenesis of
osteosarcoma. Asian Pac J Cancer Prev. 15:5967–5976. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Broadhead ML, Clark JC, Myers DE, Dass CR
and Choong PF: The molecular pathogenesis of osteosarcoma: A
review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kansara M and Thomas DM: Molecular
pathogenesis of osteosarcoma. DNA Cell Biol. 26:1–18. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tabone MD, Kalifa C, Rodary C, Raquin M,
Valteau-Couanet D and Lemerle J: Osteosarcoma recurrences in
pediatric patients previously treated with intensive chemotherapy.
J Clin Oncol. 12:2614–2620. 1994.PubMed/NCBI
|
|
8
|
Kempf-Bielack B, Bielack SS, Jurgens H,
Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G,
Kabisch SF, et al: Osteosarcoma relapse after combined modality
therapy: An analysis of unselected patients in the Cooperative
Osteosarcoma Study Group (COSS). J Clin Oncol. 23:559–568. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Davis AM, Bell RS and Goodwin PJ:
Prognostic factors in osteosarcoma: A critical review. J Clin
Oncol. 12:423–431. 1994.PubMed/NCBI
|
|
10
|
Arends MJ and Wyllie AH: Apoptosis:
mechanisms and roles in pathology. Int Rev Exp Pathol. 32:223–254.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jacobson MD, Weil M and Raff MC:
Programmed cell death in animal development. Cell. 88:347–354.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cross TG, Scheel-Toellner D, Henriquez NV,
Deacon E, Salmon M and Lord JM: Serine/threonine protein kinases
and apoptosis. Exp Cell Res. 256:34–41. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aggarwal BB and Takada Y: Pro-apoptotic
and anti-apoptotic effects of tumor necrosis factor in tumor cells.
Role of nuclear transcription factor NF-κB. Cancer Treat Res.
126:103–127. 2005. View Article : Google Scholar
|
|
14
|
Graham B and Gibson SB: The two faces of
NF-κB in cell survival responses. Cell Cycle. 4:1342–1345. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lamkanfi M, Declercq W, Van den Berghe T
and Van den Abeele P: Caspases leave the beaten track:
caspase-mediated activation of NF-κB. J Cell Biol. 173:165–171.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Piva R, Belardo G and Santoro MG: NF-κB: a
stress-regulated switch for cell survival. Antioxid Redox Signal.
8:478–486. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Radhakrishnan SK and Kamalakaran S:
Pro-apoptotic role of NF-κB: implications for cancer therapy.
Biochim Biophys Acta. 1766:53–62. 2006.PubMed/NCBI
|
|
18
|
Maeshima Y, Colorado PC, Torre A, Holthaus
KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE and
Kalluri R: Distinct antitumor properties of a type IV collagen
domain derived from basement membrane. J Biol Chem.
275:21340–21348. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hamano Y and Kalluri R: Tumstatin, the NC1
domain of α3 chain of type IV collagen, is an endogenous inhibitor
of pathological angiogenesis and suppresses tumor growth. Biochem
Biophys Res Commun. 333:292–298. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pasco S, Brassart B, Ramont L, Maquart FX
and Monboisse JC: Control of melanoma cell invasion by type IV
collagen. Cancer Detect Prev. 29:260–266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pasco S, Ramont L, Venteo L, Pluot M,
Maquart FX and Monboisse JC: In vivo overexpression of tumstatin
domains by tumor cells inhibits their invasive properties in a
mouse melanoma model. Exp Cell Res. 301:251–265. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kawaguchi T, Yamashita Y, Kanamori M,
Endersby R, Bankiewicz KS, Baker SJ, Bergers G and Pieper RO: The
PTEN/Akt pathway dictates the direct alphaVbeta3-dependent
growth-inhibitory action of an active fragment of tumstatin in
glioma cells in vitro and in vivo. Cancer Res. 66:11331–11340.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chung IS, Son YI, Ko YJ, Baek CH, Cho JK
and Jeong HS: Peritumor injections of purified tumstatin delay
tumor growth and lymphatic metastasis in an orthotopic oral
squamous cell carcinoma model. Oral Oncol. 44:1118–1126. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tanaka Y, Singh S and Aggarwal BB:
Identification of a p65 peptide that selectively inhibits NF-κB
activation induced by various inflammatory stimuli and its role in
down-regulation of NF-κB-mediated gene expression and up-regulation
of apoptosis. J Biol Chem. 279:15096–15104. 2004. View Article : Google Scholar
|
|
25
|
Fujita M, Goto K, Yoshida K, Okamura H,
Morimoto H, Kito S, Fukuda J and Haneji T: Okadaic acid stimulates
expression of Fas receptor and Fas ligand by activation of nuclear
factor kappa-B in human oral squamous carcinoma cells. Oral Oncol.
40:199–206. 2004. View Article : Google Scholar
|
|
26
|
Bertram J, Peacock JW, Tan C, Mui AL,
Chung SW, Gleave ME, Dedhar S, Cox ME and Ong CJ: Inhibition of the
phosphatidylinositol 3′-kinase pathway promotes autocrine
Fas-induced death of phosphatase and tensin homologue-deficient
prostate cancer cells. Cancer Res. 66:4781–4788. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang F, Tang E, Guan K and Wang CY: IKKβ
plays an essential role in the phosphorylation of RelA/p65 on
serine 536 induced by lipopolysaccharide. J Immunol. 170:5630–5635.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Doyle SL, Jefferies CA and O'Neill LA:
Bruton's tyrosine kinase is involved in p65-mediated
transactivation and phosphorylation of p65 on serine 536 during
NFκB activation by lipopolysaccharide. J Biol Chem.
280:23496–23501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shiraki K, Yamanaka T, Inoue H, Kawakita
T, Enokimura N, Okano H, Sugimoto K, Murata K and Nakano T:
Expression of TNF-related apoptosis-inducing ligand in human
hepatocellular carcinoma. Int J Oncol. 26:1273–1281.
2005.PubMed/NCBI
|
|
30
|
Sakurai H, Chiba H, Miyoshi H, Sugita T
and Toriumi W: IκB kinases phosphorylate NF-κB p65 subunit on
serine 536 in the transactivation domain. J Biol Chem.
274:30353–30356. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Madrid LV, Mayo MW, Reuther JY and Baldwin
AS Jr: Akt stimulates the transactivation potential of the RelA/p65
subunit of NF-κB through utilization of the IκB kinase and
activation of the mitogen-activated protein kinase p38. J Biol
Chem. 276:18934–18940. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sasaki CY, Barberi TJ, Ghosh P and Longo
DL: Phosphorylation of RelA/p65 on serine 536 defines an
IκBα-independent NF-κB pathway. J Biol Chem. 280:34538–34547. 2005.
View Article : Google Scholar : PubMed/NCBI
|
